2024 ESMO Congress reveals T-DXd demonstrated significant progression-free survival and brain tumor reduction in advanced HER2-positive breast cancer.

A clinical trial led by Dana-Farber Cancer Institute revealed trastuzumab deruxtecan (T-DXd) is effective against brain metastases in advanced HER2-positive breast cancer. The DESTINY-Breast12 trial showed a median progression-free survival of 17.3 months, with 71% of patients experiencing tumor reduction in the brain and 90% surviving one year after treatment. The findings, presented at the ESMO Congress 2024, suggest T-DXd could be a key treatment option.

September 13, 2024
12 Articles